What is Enable Injections?
Headquartered in Cincinnati, Enable Injections is a global healthcare innovation company dedicated to transforming the patient treatment experience. The company is best known for its proprietary enFuse On-Body Delivery System, a sophisticated wearable technology engineered to facilitate the subcutaneous administration of large-volume biologics and therapeutics. By streamlining the delivery process, the enFuse system addresses critical challenges in patient compliance and healthcare economics, positioning the company as a vital player in the life sciences and digital health ecosystem. The firm's market position is defined by its ability to bridge the gap between complex pharmaceutical requirements and user-friendly, at-home administration solutions.
How much funding has Enable Injections raised?
Enable Injections has raised a total of $309M across 7 funding rounds:
Private Equity
$2M
Multiple Rounds
$60M
Debt
$2M
Series C
$215M
Other Financing Round
$30M
Private Equity (2012): $2M, investors not publicly disclosed
Private Equity (2016): $5M, investors not publicly disclosed
Private Equity (2016): $25M, investors not publicly disclosed
Series A (2016): $30M featuring Cincinnati Childrenu2019s Hospital Medical Center, CincyTech, and Cintrifuse
Debt (2020): $2M backed by PPP
Series C (2022): $215M with participation from Squarepoint Capital, Magnetar Capital, and GCM Grosvenor
Other Financing Round (2026): $30M led by Sanofi
Key Investors in Enable Injections
Squarepoint Capital
A leading global investment management firm that leverages quantitative strategies and automated trading systems to execute across diverse financial markets.
Magnetar Capital
An Evanston-based financial investment firm with deep expertise in hedge fund management and the collateralized debt obligation market.
GCM Grosvenor
A global alternative asset management solutions provider that specializes in multi-strategy, credit-focused, and private equity investments for institutional clients.
What's next for Enable Injections?
With the recent influx of capital, Enable Injections is well-positioned to accelerate the commercialization and manufacturing scale-up of its enFuse platform. The strategic nature of this funding suggests a focus on deepening partnerships with global pharmaceutical entities to integrate the delivery system into broader therapeutic pipelines. As the company moves beyond its initial development phases, the focus will likely shift toward expanding its clinical footprint and optimizing supply chain capabilities to meet the growing demand for patient-friendly, high-volume subcutaneous delivery solutions. This growth phase is expected to further solidify the company's influence in the biopharmaceutical sector, driving long-term value through technological differentiation and improved patient outcomes.
See full Enable Injections company page
